Protagonist Therapeutics PE ratio PTGX

Share price divided by earnings per share over the last twelve months, since 2024.

Today, Oct 23, 2026: 134×
2-year median: 58.3×
Against its 2-year history: 81st; percentile: 0 is its lowest day, 100 its highest
2-year range: 8.9× to 154×
Peer median: 60.3×

Protagonist Therapeutics' PE ratio is 134× as of Oct 23, 2026: a share price of $138.43 against $1.03 of earnings per share over the last twelve months.

That is above its 2-year median of 58.3×, higher than on 81% of days in the last 2 years.

Over that time it ranged from 8.9× in Feb 2025 to 154× in Dec 2025.

The median for 10 large drugmakers of a similar size is 60.3×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	134×	125×	151×
2025	143×	8.9×	154×
2024	14.6×	11.5×	18.0×

Against its peers

Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first, today.

Company	PE ratio
PTGXProtagonist Therapeutics	134×
CORTCorcept Therapeutics	204×
TGTXTG Therapeutics	19.8×
BMRNBiomarin Pharmaceutical	151×
ALKSAlkermes plc.	115×
AMRXAmneal Pharmaceuticals	41.6×
LGNDLigand Pharmaceuticals	32.3×
KNSAKiniksa Pharmaceuticals International	79.1×
JAZZJazz Pharmaceuticals	14.6×
INDVIndivior Pharmaceuticals	12.4×
ARQTArcutis Biotherapeutics	142×
Peer median	60.3×

Where Protagonist Therapeutics ranks

#38of 41Large drugmakers with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Protagonist Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.